Long-term study of Ezefeno added to statin for high cholesterol and diabetes
Tests Ezefeno with a statin in adults with high cholesterol and type 2 diabetes.
Key facts
- Who runs it
- Korea University Anam Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
- Status
- Recruiting
- People taking part
- 3,958 people, planned
- Started
- 1 Mar 2024
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
- Dose escalation of moderate-intensity statin
- Record updated
- 27 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and high blood fats who are not well controlled on a moderate-intensity statin and have a heart or vessel risk factor.
- Age
- 19 years or older
- Sex
- Women and men can join.
- Disease stage
- Type 2 diabetes with high blood fats: non-HDL-C 100 mg/dL (2.6 mmol/L) or more and TG 200 mg/dL (5.2 mmol/L) or more but under 500 mg/dL (12.9 mmol/L), on a moderate-intensity statin.
- Earlier treatment
- Must be taking a moderate-intensity statin.
- Biomarker or test result
- Non-HDL-C ≥100 mg/dL (2.6 mmol/L) and TG ≥200, <500 mg/dL.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Uncontrolled high blood sugar (more than 12.0% for people on diabetes treatment)
- Muscle disease (myopathy) or rhabdomyolysis
- AST/ALT more than 3 times the upper limit of normal
- Genetic disorders such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with type 2 diabetes diagnosed by American Diabetes Association criteria
- Age ≥ 19 years
- Non-HDL-C ≥100 mg/dL, TG ≥200, <500 mg/dL on moderate-intensity statins
- with cardiovascular risk factor
Who cannot take part
- Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.)
- AST/ALT more than 3 ULN
- Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption
- Pregnant or breastfeeding women
- Patient with myopathy and rhabdomyolysis
Where in South Korea
- Korea University Anam HospitalSeoul, South KoreaContact: Sin Gon Kim, MDTaking people
About the trial
What the trial wants to find out
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:
Read full original descriptionShow less
* major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
The 2 groups in the trial
- Treatment groupTreatment being tested
Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
Treatment: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
- Control groupExisting treatment, for comparison
Dose escalation of moderate-intensity statin
Treatment: Dose escalation of moderate-intensity statin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of Non-HDL-C Levels Even With Moderate-intensity Monotherapy
- Plain-language title
- Long-term study of Ezefeno added to statin for high cholesterol and diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).Endocrinology and metabolism (Seoul, Korea), 2024
- Record updated
- 27 August 2024